CD33 and myelodysplastic syndrome: Other NKCEs under assessment in haematological malignancies included a TriKE (GTB-3550) targeting CD16, IL-15, and the tumour-associated antigen CD33 in AML and high-risk myelodysplastic syndromes in a phase 1 trial (NCT03214666).